PriceTargets.com logo

BerGenBio ASA - BRRGF Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.03 As of 04/17/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for BRRGF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BerGenBio ASA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BRRGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BRRGF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for BerGenBio ASA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.03.

This chart shows the closing price for BRRGF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in BerGenBio ASA. This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/26/2023DNB MarketsDowngradeHold ➝ Sell
11/28/2022HC WainwrightUpgradeNeutral ➝ Buy
9/12/2022DNB MarketsDowngradeBuy ➝ Hold
5/4/2022HC WainwrightDowngradeBuy ➝ Neutral
3/8/2021HC WainwrightReiterated RatingBuy
3/11/2020HC WainwrightReiterated RatingBuy ➝ Average
12/11/2019HC WainwrightReiterated RatingBuy
(Data available from 4/18/2019 forward)

News Sentiment Rating

-1.71 (Strong Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BerGenBio ASA logo
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Read More

Today's Range

Now: $0.03
Low: $0.03
High: $0.03

50 Day Range

MA: $0.02
Low: $0.03
High: $0.03

52 Week Range

Now: $0.03
Low: $0.03
High: $0.03

Volume

N/A

Average Volume

200 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BerGenBio ASA?

The following Wall Street analysts have issued stock ratings on BerGenBio ASA in the last year: DNB Markets.
View the latest analyst ratings for BRRGF.

What is the current price target for BerGenBio ASA?

0 Wall Street analysts have set twelve-month price targets for BerGenBio ASA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BerGenBio ASA in the next year.
View the latest price targets for BRRGF.

What is the current consensus analyst rating for BerGenBio ASA?

BerGenBio ASA currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe BRRGF will underperform the market and that investors should sell shares of BerGenBio ASA.
View the latest ratings for BRRGF.

What other companies compete with BerGenBio ASA?

Other companies that are similar to BerGenBio ASA include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to BerGenBio ASA.

How do I contact BerGenBio ASA's investor relations team?

BerGenBio ASA's physical mailing address is Jonas Lies Vei 91, Bergen, Hordaland 5009. The company's listed phone number is 47 53 50 15 64. The official website for BerGenBio ASA is www.bergenbio.com. Learn More about contacing BerGenBio ASA investor relations.